Salvage treatment of unfavorable non-Hodgkin's lymphoma with cisplatin, amsacrine, and mitoguazone: A Southwest Oncology Group pilot study

B. W. Dana; S. E. Jones; C. Coltman; W. J. Stuckey

Salvage treatment of unfavorable non-Hodgkin's lymphoma with cisplatin, amsacrine, and mitoguazone: A Southwest Oncology Group pilot study

B. W. Dana, S. E. Jones, C. Coltman, W. J. Stuckey

Research output: Contribution to journal › Article › peer-review

Abstract

We tested the combination of cisplatin, amsacrine, and mitoguazone as salvage treatment for patients with advanced unfavorable non-Hodgkin's lymphomas. An objective response rate of 43% was noted in 30 evaluable patients, but all responses were partial and the median duration of response was only 2 months. Toxicity included life-threatening and fatal leukopenia and severe gastrointestinal intolerance. We conclude that this combination chemotherapy regimen is not a valuable salvage treatment for patients with non-Hodgkin's lymphoma.

Original language	English (US)
Pages (from-to)	291-292
Number of pages	2
Journal	Cancer Treatment Reports
Volume	70
Issue number	2
State	Published - 1986
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{e96bb6f4ea2a4c54a4ae3a62f144a759,

title = "Salvage treatment of unfavorable non-Hodgkin's lymphoma with cisplatin, amsacrine, and mitoguazone: A Southwest Oncology Group pilot study",

abstract = "We tested the combination of cisplatin, amsacrine, and mitoguazone as salvage treatment for patients with advanced unfavorable non-Hodgkin's lymphomas. An objective response rate of 43% was noted in 30 evaluable patients, but all responses were partial and the median duration of response was only 2 months. Toxicity included life-threatening and fatal leukopenia and severe gastrointestinal intolerance. We conclude that this combination chemotherapy regimen is not a valuable salvage treatment for patients with non-Hodgkin's lymphoma.",

author = "Dana, {B. W.} and Jones, {S. E.} and C. Coltman and Stuckey, {W. J.}",

year = "1986",

language = "English (US)",

volume = "70",

pages = "291--292",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Salvage treatment of unfavorable non-Hodgkin's lymphoma with cisplatin, amsacrine, and mitoguazone

T2 - A Southwest Oncology Group pilot study

AU - Dana, B. W.

AU - Jones, S. E.

AU - Coltman, C.

AU - Stuckey, W. J.

PY - 1986

Y1 - 1986

N2 - We tested the combination of cisplatin, amsacrine, and mitoguazone as salvage treatment for patients with advanced unfavorable non-Hodgkin's lymphomas. An objective response rate of 43% was noted in 30 evaluable patients, but all responses were partial and the median duration of response was only 2 months. Toxicity included life-threatening and fatal leukopenia and severe gastrointestinal intolerance. We conclude that this combination chemotherapy regimen is not a valuable salvage treatment for patients with non-Hodgkin's lymphoma.

AB - We tested the combination of cisplatin, amsacrine, and mitoguazone as salvage treatment for patients with advanced unfavorable non-Hodgkin's lymphomas. An objective response rate of 43% was noted in 30 evaluable patients, but all responses were partial and the median duration of response was only 2 months. Toxicity included life-threatening and fatal leukopenia and severe gastrointestinal intolerance. We conclude that this combination chemotherapy regimen is not a valuable salvage treatment for patients with non-Hodgkin's lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=0022620665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022620665&partnerID=8YFLogxK

M3 - Article

C2 - 3753898

AN - SCOPUS:0022620665

VL - 70

SP - 291

EP - 292

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 2

ER -

Salvage treatment of unfavorable non-Hodgkin's lymphoma with cisplatin, amsacrine, and mitoguazone: A Southwest Oncology Group pilot study

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this